

JAN. 14. 2004 3:58PM


OBLON SPIVAK

NO. 658 P. 1

RECEIVED
CENTRAL FAX CENTER

MAR 18 2004

Unofficial



ATTORNEYS AT LAW

1940 DUKE STREET
ALEXANDRIA, VIRGINIA 22314
USA

(703) 413-3000
(703) 413-2220 FACSIMILE

OBLONPAT@OBLON.COM

PATENT, TRADEMARK AND COPYRIGHT LAW
AND RELATED FEDERAL AND ITS LITIGATION

WWW.OBLON.COM

FACSIMILE

PLEASE CALL US AT (703) 413-3000 IF THE MESSAGE YOU RECEIVE IS INCOMPLETE OR NOT LEGIBLE

TO	ELIZABETH SLOBODYANSKI	Jan. 14, 2004
NAME	ART UNIT 1652	DATE
COMPANY/FIRM		FAX# 703 746-5089
NUMBER OF PAGES INCLUDING COVER:	2	CONFIRM FAX: <input type="checkbox"/> YES <input type="checkbox"/> NO
FROM	Thomas Cunningham	193582US-0
NAME	703-413-6563	OUR REFERENCE
DIRECT PHONE #		YOUR REFERENCE 09/581,241

MESSAGE

Dear Examiner Slobodyanski,

As discussed, attached is a proposed base claim. To simplify the claim language I propose revising the Sequence Listing to include SEQ ID NOS: (7 and) 8, the native luciferase (NA and) AA sequences from which SEQ ID NOS: (3 and 5) 4 and 6 were derived. The attached page indicates support for the other limitations in the proposed claim. If this language is acceptable, the remaining claims can be revised for consistency.

Sincerely,
Thomas Cunningham

Unless otherwise indicated or obvious from the nature of the transmittal, the information contained in this facsimile message is attorney privileged and confidential information intended for the use of the individual or entity named above. If the reader of this message is not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error or are not sure whether it is privileged, please immediately notify us by telephone and return the original message to us at the above address via the U.S. Postal Service at our Expense. Thank You.

PROPOSED BASE CLAIM FOR 09/581,241

Claim 100 (proposed): The polypeptide of SEQ ID NO: 8* or a fragment of SEQ ID NO: 8*,

wherein said polypeptide or said polypeptide fragment has luciferase activity and retains at least 85% of its luciferase activity in the presence of 0.4% benzalkonium chloride compared to its luciferase activity as measured in the absence of benzalkonium chloride.

*Note: Amend Sequence Listing to define SEQ ID NO: 8 as the same sequence as SEQ ID NO: 4 (or 6), except that residues 271 and 490 are defined as Xaa. Xaa at position 271 is any amino acid except alanine (the native residue). Xaa at position 490 is any amino acid except glutamic acid (the native residue). Support for adding SEQ ID NO: 8 is found in original SEQ ID NOS: 4 and 6 as described on pages 15-17 of the specification, see e.g., page 16, lines 5-9, and page 17, lines 8-12.

1. Support for fragments: Specification, page 3, lines 3-4 and 7-9 from page bottom.
2. Support for "at least 85% of its luciferase activity": Specification, page 5, lines 13-14.